The Future of Cancer Medicine Depends on Delivery
Breakthrough therapies such as CRISPR Cas9, SiRNA, and mRNA hold immense potential to transform cancer treatment.
Yet, these therapies face the same challenge:
Reaching the right cells safely and effectively.
OncoXome is developing a plant-derived exosome platform engineered to enable targeted oral delivery of novel therapies to cancer cells, such as colorectal & lung cancer cells.
A new generation of natural delivery vehicles
At OncoXome, we harness exosomes from carefully selected plants and engineer them to become precision delivery vehicles
Orally administered
Protect therapeutic cargo
Reach & concentrate in cancer cells
Safely deliver therapy inside cells
Support repeat dosing
Versatile loading (CRISPR Cas9, SiRNA, mRNA)
HOW THE DELIVERY PLATFORM WORKS
Plant selection
We identify plant sources capable of producing high quality exosomes with desirable biological properties.
1
Exosome isolation
Exosomes are isolated and characterized using proprietary processes.
2
Exosome Engineering
Exosomes are engineered using proprietary processes to improve loading and for precision delivery.
3
Exosome Loading
Therapeutic payloads are loaded into the exosomes:
- CRISPR Cas9
- SiRNA
- mRNA
- Other nucleic acids
4
Oral Administration
The loaded exosomes are administered orally.
5
Exosome Delivery
Engineered exosomes pass through the liver and travel to the tumor to deliver their payload, ie. cancer therapy.
6
CRISPR Cas9 Delivery
Our engineered exosomes release their cargo into the cancer cells.
1
HOW THE THERAPEUTIC PLATFORM WORKS
Mutation Detection
CRISPR Cas9 detects the cancer mutation in the cancer cell.
.png)
2
Mutation Knockout
CRISPR Cas9 Knocks out the driving oncogene mutation.
.png)
3
Cancer Cell Death
Due to oncogene addiction, knocking out the driving oncogene leads to apoptosis (cancer cell death).
.png)
4
VALIDATED APPROACH IN VIVO
DEMONSTRATED DELIVERY OF FUNCTIONAL CRISPR CAS9
We have demonstrated that our engineered plant-derived exosomes can deliver mRNA, SiRNA, and CRISPR Cas9 to colorectal tumor cells and drive meaningful anti-tumor activity in vivo.
Tumor Reduction & Control
Observed in vivo in colorectal cancer models
.png)
Successful Targeting & Delivery
Successful delivery of payloads in tumor cells.
Oral Administration
Platform designed for effective oral delivery
Safe, No Toxicity Reported
5X exosome dose administered. No change in:
- body weight
- behavior
- general health status